Biocartis Announces Commercial Launch of a New Biomarker Analysis Platform

Lausanne, Switzerland (ots/PRNewswire) -

Biocartis launches its revolutionary detection platform, Dynamic
Multi-Analyte Technology ("DMAT"):

- New proteomic and nucleic acid platform provides ultra-high quality data
analysis even at higher multiplex formats.
- Platform launched well ahead of plan. Biocartis flips from a late-stage
development company into a commercial business.

Accurate and fast validation of biomarkers; increasing efficiency
in Research and Drug Development

DMAT is an innovative and integrated detection platform for
high-quality biomarker analysis. It enables accelerated development
of multiplex assays where several biomarkers can be analyzed at the
same time. DMAT dramatically reduces hands-on time and allows users
to perform bioassays far more quickly and cost-effectively than with
other systems, while ensuring optimal accuracy.

"This revolutionary technology will accelerate the conversion of
biomarker discoveries into clinical practice and will help scientists
deliver more quickly the promise of personalized medicine," said
Biocartis CEO Dr. Greg Parekh. "DMAT is complementary with protein
biomarker discovery and next generation sequencing, because the ease
of use, sensitivity and accuracy enables rapid validation of new
biomarkers initially identified on these other platforms."

Innovative detection technology combining reproducibility, speed
and multiplexing

Conceived in 2007 and developed under design control, DMAT
leverages advanced semi-conductor technologies and micro-fluidics to
provide fast, flexible and multiplexed detection and quantification
of nucleic acid and protein based biomarkers. The platform
accelerates biomarker research and yields robust and highly
reproducible data over a wide range of analyte concentrations.
Demonstrating concordance between single-plex and multiplex assays,
the DMAT platform can measure over 2000 analytes simultaneously
without deterioration in performance.

For Research Use Only ("RUO")

The DMAT platform is initially targeting the research market. As
such, Biocartis is offering customizable generic test consumables to
maximize application flexibility. Biocartis is additionally
developing a menu of important RUO assays including a cytokine panel,
an oncogene panel and a cell signaling panel.

With the commercialization of DMAT, Biocartis is scaling up its
sales force to initially target the Preclinical, Clinical Development
and Clinical Research markets.

http://www.biocartis.com

ots Originaltext: Biocartis
Im Internet recherchierbar: http://www.presseportal.de

Contact:
Greg Parekh, CEO: Tel: +41-21-694-04-30, pr@biocartis.com /
Allison Ballmer, Global Marketing Manager DMAT: Tel:
+41-78-604-83-19,
aballmer@biocartis.com